Company: VRCA
Filing Date: 2025-12-15
Form Type: S-3
Source: 0001193125-25-319225
Chunk: 14

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-12-15
Form: S-3
Chunk 14
---
 does not reflect this limitation. Caligan serves indirectly as the investment manager to the Caligan Fund and the Caligan Accounts. David Johnson is the managing member of Caligan and 
 Managing Member of Caligan Partners GP LLC, the general partner of Caligan. The address of Caligan is 780 Third Avenue, 30th Floor, New York, New York 10017.                                                                                             |

| (10) | “Beneficial Ownership Prior to this Offering” consists of (a) 639,193 shares of common stock held                                                                                                                                                       
 by Armistice Capital Master Fund Ltd. (the “Master Fund”) prior to the Private Placement, (b) 561,797 shares of our common stock issuable upon exercise of Series B warrants held by Master Fund prior to the Private Placement, (c)                    
 1,178,925 shares of our common stock issuable upon exercise of Pre-Funded Warrants issued to the Master Fund in the Private Placement and (d) 294,731 shares of our common stock issuable upon exercise of Common                                       
 Warrants issued to Armistice Capital Master Fund Ltd. in the Private Placement (together with (b) and (c), the “Armistice Warrants”). Pursuant to the terms of the Armistice Warrants, the holder of such Armistice Warrants does not                   
 have the right to exercise any portion of the Armistice Warrants, to the extent that, after giving effect to such exercise, such holder would beneficially own a number of shares of common stock in excess of 9.99% of the shares of common stock then 
 issued and outstanding. Armistice Capital, LLC (“Armistice”) is the investment manager of the Master Fund, and pursuant to an Investment Management Agreement, Armistice exercises voting and investment power over the securities held by              
 the Master Fund and thus may be deemed to beneficially own the securities held by the Master Fund. Steven Boyd, as the managing member of Armistice, may be deemed to beneficially own the securities held by the Master Fund. The Master Fund          
 specifically disclaims beneficial ownership of the securities directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice. The address of Armistice is 510   
 Madison Avenue, 7th Floor, New York, New York 10022.                                                                                                                                                                                                    |

| (11) | “Beneficial Ownership Prior to this Offering” consists of